The EUnetHTA planned assessment of transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis at intermediate surgical risk

Nov 2017

Italian national health technology assessment agency (Agenas) and Norwegian Institute of Public Health (NIPHO) will jointly perform a rapid assessment of transcatheter aortic valve implantation (TAVI) within EUnetHTA framework. The objective of the work will be dedicated to rapid assessment of TAVI procedure in patients with aortic stenosis at intermediate risk compared to aortic valve replacement in relation to efficacy and safety. Another purpose is a development of more than two national or local reports with results of assessment.

Some of HTA bodies and external experts from Belgium, Greece, Ireland and Switzerland will carry out a review of the draft and the final version of the assessment report.

Analysis of efficacy is planned via review of randomized controlled trials (RCTs). Safety will be evaluated within the review of RCTs and real-world evidence data.

In accordance to planned activities first draft of assessment will be ready to review till 20th of November and final version will prepared till 31st of January, 2018.

See full plan in English here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Rapid HTAs of five medical devices released in Tuscany

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Belgian KCE developing procedure for assessment of digital health technologies

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Assessments of monitoring and diagnostics of atrial fibrillation products released in Sweden

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

HTAs published by FinCCHTA in February 2022

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Theme survey on products for monitoring and diagnostics of sepsis launched by Swedish TLV

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.